Somagenetix: Funding, Investors & Team (Sep 2026)
Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, long-term efficacy and safety. Our goal is to cure patients with immunodeficiency, neurodegeneration and cancer with brain metastasis via genetically enhanced phagocytes.
Somagenetix has raised $11.7M across 1 funding round on record, the most recent a Series A of $11.7M announced in Oct 2024.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Somagenetix Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Somagenetix Funding Rounds
Somagenetix Founders and Leadership Team
Contact details for the Somagenetix team: 1 of 1 has an email address on file.
Start 14-day free trial →Somagenetix Funding Compared to Other Health Care Startups
Somagenetix's latest round of $11.7M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Somagenetix in Health Care and Zürich
Companies Similar to Somagenetix
MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.
CeQur Simplicity helps people with diabetes by developing drug-delivery devices. They develop bolus insulin…
Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify…
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for…
UNBOOUND is a medtech company and university spin-off (The Rockefeller University and University of Geneva)…
Christina Vallgren and Marcus Palm, two physicists from CERN, co-founded Terapet along with Professor Raymond…
Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of…
Babylat is an enricher device is the first automated, small-scale tabletop device for the protein enrichment…
Altiscreen is creating and producing cutting-edge, portable drug-of-abuse detection systems. With the use of…
Vivent provides growers, breeders and agrochem companies with actionable information direct from plants…
Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded…
Somagenetix Funding FAQs
What does Somagenetix do?
Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, long-term efficacy and safety. Our goal is to cure patients with immunodeficiency, neurodegeneration and cancer with brain metastasis via genetically enhanced phagocytes.
How much funding has Somagenetix raised?
Somagenetix has raised $11.7M across 1 round on record. The most recent is a Series A of $11.7M announced in Oct 2024.
When did Somagenetix last raise funding?
Somagenetix's most recent funding round on record is a Series A of $11.7M, announced in Oct 2024.
Who founded Somagenetix?
FundedIQ lists Janine Reichenbach (Founder) at Somagenetix.
Where is Somagenetix headquartered?
Somagenetix is based in Zürich, Zurich, Switzerland.
How many employees does Somagenetix have?
Somagenetix is in the 1-10 employee band.
How does Somagenetix's funding compare to other Health Care startups?
Somagenetix's latest round of $11.7M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Somagenetix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Somagenetix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.